Lead Product(s): Tafasitamab
Therapeutic Area: Oncology
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Deal Size: $2,000 million Upfront Cash: $750.0 million
Deal Type: Collaboration January 13, 2020
MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.